“Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma”, Mol. Med. Com., vol. 3, no. 02, pp. 89–92, Dec. 2023, doi: 10.55627/mmc.003.02.0461.